When Product Claims Blur the Line: What the Botox® Case Shows About Power, Perception, and Proof
The High Court held that “instant Botox® alternative” was not used as a trade mark and conveyed no long-term efficacy claim. This case shows how assumptions about brand strength and reputation can drive unnecessary escalation. Clean Law’s one-path funding model is built to prevent those escalations before they become costly.
When “Not Warning” Isn’t Misleading: The High Court on Contingent Risks and Commercial Silence
The High Court in Lundbeck held Sandoz had no duty to warn of a contingent patent risk. Clean Law’s independence safeguards help clients avoid blind spots created by conflicted advice.